Solara Active Pharma Sciences Limited

NSE SOLARA.NS

Solara Active Pharma Sciences Limited Capital Expenditure for the year ending March 31, 2024: USD -4.92 M

Solara Active Pharma Sciences Limited Capital Expenditure is USD -4.92 M for the year ending March 31, 2024, a 63.65% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Solara Active Pharma Sciences Limited Capital Expenditure for the year ending March 31, 2023 was USD -13.54 M, a 50.71% change year over year.
Solara Active Pharma Sciences Limited Capital Expenditure for the year ending March 31, 2022 was USD -27.48 M, a -15.30% change year over year.
Solara Active Pharma Sciences Limited Capital Expenditure for the year ending March 31, 2021 was USD -23.83 M, a 33.21% change year over year.
Solara Active Pharma Sciences Limited Capital Expenditure for the year ending March 31, 2020 was USD -35.68 M, a -371.89% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

NSE: SOLARA.NS

Solara Active Pharma Sciences Limited

CEO	Mr. Poorvank Purohit
IPO Date	June 27, 2018
Location	India
Headquarters	Admin Block 27
Employees	2,156
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Drugstores & Retail Pharmacies Non-Alcoholic Beverages Personal Care

Description

Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India. The company offers APIs for anesthetics, anthelmintic, anti-arrhythmic agent, anti-asthmatic, anti-hypertensive, anti-inflammatory, anti-Parkinson, anti-viral, antibiotic, anticoagulant, anticonvulsant, antidepressant, antiemetic, antiepileptic, antifungal, antigout agent, antihistamine, antihyperlipoproteinemic, antimalarial, antimycotic, antineoplastic detoxifying agent, antiprotozoal agent, antipsoriatic, antipsychotic, antitubercular, antitussive, antiulcerative, anxiolytic, bile acid analogue, calcimimetic agent, cardiovascular agent, central nervous system agent, chronic alcoholism, chronic kidney disease, dopamine receptor antagonist, folate analog, hyperkalaemia, immunosuppressant, lipid regulating agent, loop diuretic, muscarinic agonist, neuromuscular, OAB treatment, phenylalanine reducer, recovery of stroke, tardive dyskinesia, treatment of glaucoma and hyperphosphatemia, tropical anti-infective, and type-II diabetes therapeutic categories. It also provides contract research and manufacturing services for APIs, including contract development and manufacturing, analytical services, impurity synthesis, and regulatory support. In addition, the company exports its products. It operates in the Asia Pacific, Europe, North America, South America, and internationally. The company was formerly known as SSL Pharma Sciences Limited and changed its name to Solara Active Pharma Sciences Limited in March 2017. Solara Active Pharma Sciences Limited was incorporated in 2017 and is based in Chennai, India.

Key trends

Past 5 years